108 related articles for article (PubMed ID: 10079873)
1. [Pharmacokinetic basis for the use of pefloxacin in severe forms of infectious-inflammatory diseases].
Navashin PS; Smirnova LB
Antibiot Khimioter; 1998; 43(12):30-8. PubMed ID: 10079873
[No Abstract] [Full Text] [Related]
2. [Pefloxacin mesylate--clinical effectiveness in various forms of infectious-inflammatory diseases].
Pozdniakova VP; Nestetrova LIa; Smirnova LB; Iakovlev VP; Blatun LA; Koshil' OI; Fedorov SM; Bakalova LA; Strachunskiĭ LS; Kurmanova KB
Antibiot Khimioter; 1997; 42(7):20-3. PubMed ID: 9334143
[TBL] [Abstract][Full Text] [Related]
3. [Pefloxacin (Abactal): role in modern therapy of bacterial infections].
Fomina IP; Smirnova LB
Antibiot Khimioter; 2000; 45(8):42-7. PubMed ID: 10989724
[No Abstract] [Full Text] [Related]
4. Release of pefloxacin bonded on catheters after intraperitoneal implantation in mice.
Carsenti-Etesse H; Forget B; Bensoussan M; Bensoussan F; Dellamonica P
Drugs; 1995; 49 Suppl 2():304-6. PubMed ID: 8549342
[No Abstract] [Full Text] [Related]
5. [Pefloxacin (Abaktal)--efficacy in treating severe infections, optimization of treatment based on pharmacokinetic and pharmacodynamic parameters].
Budanov SV; Vasil'ev AN; Smirnov LB
Antibiot Khimioter; 2002; 47(12):31-6. PubMed ID: 12728632
[No Abstract] [Full Text] [Related]
6. [Fluoroquinolones in clinical practice. Pefloxacin (abaktal, peflacine)].
Fomina IP; Iudin SM; Kashina LB
Antibiot Khimioter; 1995; 40(11-12):70-7. PubMed ID: 8830644
[No Abstract] [Full Text] [Related]
7. [Evaluation of the effectiveness of the use of pefloxacin in combined radiation-thermal injury].
Makarov GF; Budagov RS; Moiseeva LA; Boldueva NG
Antibiot Khimioter; 1995 Aug; 40(8):36-9. PubMed ID: 8713436
[TBL] [Abstract][Full Text] [Related]
8. Pefloxacin in the treatment of acute severe infections in hospitalized patients. Clinical and bacteriological evaluation.
Giustina A; Romanelli G; Cravarezza P; Ravizzola G; Turano A
J Chemother; 1989 Jul; 1(4 Suppl):668-9. PubMed ID: 16312584
[No Abstract] [Full Text] [Related]
9. Efficacy of pefloxacin in the treatment of postoperative sepsis in gynaecology.
Arowojolu AO; Bakare RA; Oni AA; Ayodele AE; Kayode OO
Afr J Med Med Sci; 1999; 28(3-4):151-3. PubMed ID: 11205820
[TBL] [Abstract][Full Text] [Related]
10. [Clinical and pharmacokinetic study of pefloxacin in spontaneous ascitic fluid infections].
Ducroix JP; Hary L; Andrejak M; Smail A; Tondriaux A; Eb F; Baillet J
Therapie; 1990; 45(6):461-5. PubMed ID: 2080483
[TBL] [Abstract][Full Text] [Related]
11. [Use of pefloxacin in the treatment of infected burn wounds].
Iakovlev VP; Alekseev AA; Krutikov MG; Grishina IA; Izotova GN
Antibiot Khimioter; 1996 Jun; 41(6):39-43. PubMed ID: 9054328
[TBL] [Abstract][Full Text] [Related]
12. Pefloxacin penetration into human necrotic pancreatic tissue.
Bertazzoni Minelli E; Benini A; Muner A; Bassi C; Abbas H; Pederzoli P
J Antimicrob Chemother; 1996 Aug; 38(2):237-43. PubMed ID: 8877537
[TBL] [Abstract][Full Text] [Related]
13. [Initial antibiotherapy in severe bacterial bronchopneumopathies. Randomized study of a new quinolone: pefloxacin].
Fourrier F; Chopin C; Lestavel P; Savage C
Presse Med; 1986 Jun; 15(26):1240. PubMed ID: 2944094
[No Abstract] [Full Text] [Related]
14. Effects of norfloxacin or pefloxacin on the oral and intestinal microflora of bone marrow transplant patients.
Giuliano M; Gentile G; Pantosti A; Micozzi A; Arcese W; Martino P
J Chemother; 1989 Jul; 1(4 Suppl):726-7. PubMed ID: 16312609
[No Abstract] [Full Text] [Related]
15. [Pefloxacine and severe eye infections].
Massin-Cochereau I; Le Hoang P; Weiser M; Rousselie F
Bull Soc Ophtalmol Fr; 1987; 87(6-7):735-6, 738. PubMed ID: 3499243
[No Abstract] [Full Text] [Related]
16. [Clinical effectiveness of pefloxacin (abaktal)in the treatment of inflammatory diseases of the kidneys, urinary tracts and genital organs].
Lopatkin NA; Darenkov AF; Derevianko II; Perepanova TS; Kotliarova GA; Nosova TA
Antibiot Khimioter; 1993; 38(2-3):44-9. PubMed ID: 8074566
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics of intravenously administered pefloxacin in the prostate; perspectives for its application in surgical prophylaxis.
Giannopoulos A; Koratzanis G; Giamarellos-Bourboulis EJ; Stinios I; Chrisofos M; Giannopoulou M; Giamarellou H
Int J Antimicrob Agents; 2001 Mar; 17(3):221-4. PubMed ID: 11282268
[TBL] [Abstract][Full Text] [Related]
18. Pefloxacin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.
Gonzalez JP; Henwood JM
Drugs; 1989 May; 37(5):628-68. PubMed ID: 2663414
[TBL] [Abstract][Full Text] [Related]
19. [Pefloxacin (abactal) efficacy in severe pneumonia].
Aleksanian LA
Antibiot Khimioter; 2001; 46(4):19-21. PubMed ID: 11550502
[No Abstract] [Full Text] [Related]
20. Comparative activities of pefloxacin and ciprofloxacin in the treatment of chronic respiratory tract infections.
Scaglione F; Scamazzo F; Arcidiacono MM; Cogo R; Monzani GP; Fraschini F
J Chemother; 1995 Apr; 7(2):140-5. PubMed ID: 7666121
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
